Autonomic dysfunction as manifestation of ICANS: A case report

[Rationale]: Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy is a successful treatment for B-cell malignancies associated with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Cardiovascular toxicities have also been reported in this sett...

Descripción completa

Detalles Bibliográficos
Autores: Rochate, Dina, González-García, Antonio Manuel, Marcos Santos, Carmen, Pérez-López, Estefanía, Martín López, Ana África, Alaña, Mónica, Martín-Martín, Lourdes, López-Parra, Miriam, Sánchez-Guijo, Fermín M., López-Corral, Lucía
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/387555
Acceso en línea:http://hdl.handle.net/10261/387555
Access Level:acceso abierto
Palabra clave:Chimeric antigen receptor T cells-dysautonomia
Diffuse large B-cell lymphoma
ICANS
Neurotoxicity
Tachycardia
Descripción
Sumario:[Rationale]: Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy is a successful treatment for B-cell malignancies associated with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Cardiovascular toxicities have also been reported in this setting. However, there is scarce data regarding development of autonomic disorders after CAR-T cell therapy.

Similares en LA Referencia